Citations

Clear

2416 citation(s) found for "Yu, Jason L".

Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201)
Luke, Jason J. , Olson, Daniel J. , Allred, Jacob B., Bao, Riyue , Zha, Yuanyuan , Labadie, Brian , Bastos, Bruno R. , Butler, Marcus O. , Hogg, David , Strand, Carrie A, Zha, Yuanyuan , Butler, Marcus O , Luke, Jason J , Strand, Carrie , Carll, Timothy Clifford , Münster, Pamela N. , Schwartz, Gary K. , Olson, Daniel

Mayo Clinic

Clinical Cancer Research | September 26, 2019 | Volume: 26 | Issue: 4 | Pages: 804-811

10.1158/1078-0432.ccr-19-1223 | PMID 31558480 Get It

Abstract Purpose: The surface receptor MET is highly expressed on primary uveal melanoma; MET inhibitors demonstrated early clinical signals of efficacy in slowing uveal melanoma growth. The primary objective of our study was to compare the progression-free survival rate at 4 months (PFS4) of patients with uveal melanoma treated with cabozantinib or chemotherapy. Patients and Methods: Patients with metastatic uveal melanoma and RECIST measurable disease were randomized 2:1 to receive either cabozantinib (arm 1) versus temozolomide or dacarbazine (arm 2) with restaging imaging every two cycles. Cross-over from arm 2 to cabozantinib after progression was allowed (arm 2X). Available tumor specimens were analyzed by whole-exome sequencing (WES) and results were correlated with outcome. Results: Forty-six eligible patients were accrued with 31, 15, and 9 in arms 1, 2, and 2X, respectively. Median lines of prior therapy, including hepatic embolization, were two. Rates of PFS4 in arm 1 and arm 2 were 32.3% and 26.7% (P = 0.35), respectively, with median PFS time of 60 and 59 days (P = 0.964; HR = 0.99). Median overall survival (OS) was 6.4 months and 7.3 months (P = 0.580; HR = 1.21), respectively. Grade 3–4 Common Terminology Criteria for Adverse Events were present in 61.3%, 46.7%, and 37.5% in arms 1, 2, and 2X, respectively. WES demonstrated a mean tumor mutational burden of 1.53 mutations/Mb and did not separate OS ≤ or >1 year (P = 0.14). Known mutations were identified by WES and novel mutations were nominated. Conclusions: MET/VEGFR blockade with cabozantinib demonstrated no improvement in PFS but an increase in toxicity relative to temozolomide/dacarbazine in metastatic uveal melanoma.
A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to HSP90 Inhibition
Shee, Kevin , Wells, Jason D. , Ung, Matthew , Hampsch, Riley A. , Traphagen, Nicole A. , Liu, Stephanie C., Zeldenrust, Megan A., Wang, Liewei , Yu, Jia , Demidenko, Eugene , Kettenbach, Arminja N. , Miller, Todd W. , Cheng, Chao , Yang, Wei , Kalari, Krishna R. , Boughey, Judy C. , Cheng, Chao , Goetz, Matthew P.

Mayo Clinic

Clinical Cancer Research | September 26, 2019 | Volume: 26 | Issue: 1 | Pages: 159-170

10.1158/1078-0432.ccr-18-2213 | PMID 31558472 Get It

Abstract Purpose: We hypothesized that integrated analysis of cancer types from different lineages would reveal novel molecularly defined subgroups with unique therapeutic vulnerabilities. On the basis of the molecular similarities between subgroups of breast and ovarian cancers, we analyzed these cancers as a single cohort to test our hypothesis. Experimental Design: Identification of transcriptional subgroups of cancers and drug sensitivity analyses were performed using mined data. Cell line sensitivity to Hsp90 inhibitors (Hsp90i) was tested in vitro. The ability of a transcriptional signature to predict Hsp90i sensitivity was validated using cell lines, and cell line- and patient-derived xenograft (PDX) models. Mechanisms of Hsp90i sensitivity were uncovered using immunoblot and RNAi. Results: Transcriptomic analyses of breast and ovarian cancer cell lines uncovered two mixed subgroups comprised primarily of triple-negative breast and multiple ovarian cancer subtypes. Drug sensitivity analyses revealed that cells of one mixed subgroup are significantly more sensitive to Hsp90i compared with cells from all other cancer lineages evaluated. A gene expression classifier was generated that predicted Hsp90i sensitivity in vitro, and in cell line- and PDXs. Cells from the Hsp90i-sensitive subgroup underwent apoptosis mediated by Hsp90i-induced upregulation of the proapoptotic proteins Bim and PUMA. Conclusions: Our findings identify Hsp90i as a potential therapeutic strategy for a transcriptionally defined subgroup of ovarian and breast cancers. This study demonstrates that gene expression profiles may be useful to identify therapeutic vulnerabilities in tumor types with limited targetable genetic alterations, and to identify molecularly definable cancer subgroups that transcend lineage.
Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?
Novo, Mattia , Nowakowski, Grzegorz S. , Micallef, Ivana N. , Johnston, Patrick B. , Inwards, David J. , Botto, Barbara , Ristow, Kay M., Vitolo, Umberto , Ansell, Stephen M. , Vitolo, Umberto , Habermann, Thomas M. , Witzig, Thomas E. , Young, Jason R.

Mayo Clinic

Leukemia & Lymphoma | September 26, 2019 | Volume: 61 | Issue: 2 | Pages: 318-327

10.1080/10428194.2019.1663422 | PMID 31556355 Get It

CGRP-dependent and independent mechanisms of acute and persistent post-traumatic headache following mild traumatic brain injury in mice
Rau, Jill C. , Oyarzo, Janice, Tien, Jason , Mackenzie, Kimberly D., Stratton, Jennifer , Remeniuk, Bethany , Anderson, Trent , Rau, Jill, Schwedt, Todd, Dodick, David, Navratilova, Edita , Schwedt, Todd J. , Dodick, David W. , Porreca, Frank

Mayo Clinic

Cephalalgia | September 24, 2019 | Volume: 39 | Issue: 14 | Pages: 1762-1775

10.1177/0333102419877662 | PMID 31550910 Get It

Background Acute and persistent post-traumatic headache are often debilitating consequences of traumatic brain injury. Underlying physiological mechanisms of post-traumatic headache and its persistence remain unknown, and there are currently no approved therapies for these conditions. Post-traumatic headache often presents with a migraine-like phenotype. As calcitonin-gene related peptide promotes migraine headache, we explored the efficacy and timing of intervention with an anti- calcitonin-gene related peptide monoclonal antibody in novel preclinical models of acute post-traumatic headache and persistent post-traumatic headache following a mild traumatic brain injury event in mice. Methods Male, C57Bl/6 J mice received a sham procedure or mild traumatic brain injury resulting from a weight drop that allowed free head rotation while under minimal anesthesia. Periorbital and hindpaw tactile stimulation were used to assess mild traumatic brain injury-induced cutaneous allodynia. Two weeks after the injury, mice were challenged with stress, a common aggravator of migraine and post-traumatic headache, by exposure to bright lights (i.e. bright light stress) and cutaneous allodynia was measured hourly for 5 hours. A murine anti- calcitonin-gene related peptide monoclonal antibody was administered after mild traumatic brain injury at different time points to allow evaluation of the consequences of either early and sustained calcitonin-gene related peptide sequestration or late administration only prior to bright light stress. Results Mice with mild traumatic brain injury, but not a sham procedure, exhibited both periorbital and hindpaw cutaneous allodynia that resolved by post-injury day 13. Following resolution of injury-induced cutaneous allodynia, exposure to bright light stress re-instated periorbital and hindpaw cutaneous allodynia in injured, but not sham mice. Repeated administration of anti-calcitonin-gene related peptide monoclonal antibody at 2 hours, 7 and 14 days post mild traumatic brain injury significantly attenuated the expression of cutaneous allodynia when evaluated over the 14-day post injury time course and also prevented bright light stress-induced cutaneous allodynia in injured mice. Administration of anti-calcitonin-gene related peptide monoclonal antibody only at 2 hours and 7 days after mild traumatic brain injury blocked injury-induced cutaneous allodynia and partially prevented bright light stress-induced cutaneous allodynia. A single administration of anti-calcitonin-gene related peptide monoclonal antibody after the resolution of the peak injury-induced cutaneous allodynia, but prior to bright light stress challenge, did not prevent bright light stress-induced cutaneous allodynia. Conclusions We used a clinically relevant mild traumatic brain injury event in mice along with a provocative stimulus as novel models of acute post-traumatic headache and persistent post-traumatic headache. Following mild traumatic brain injury, mice demonstrated transient periorbital and hindpaw cutaneous allodynia suggestive of post-traumatic headache-related pain and establishment of central sensitization. Following resolution of injury-induced cutaneous allodynia, exposure to bright light stress re-established cutaneous allodynia, suggestive of persistent post-traumatic headache-related pain. Continuous early sequestration of calcitonin-gene related peptide prevented both acute post-traumatic headache and persistent post-traumatic headache. In contrast, delayed anti-calcitonin-gene related peptide monoclonal antibody treatment following establishment of central sensitization was ineffective in preventing persistent post-traumatic headache. These observations suggest that mechanisms involving calcitonin-gene related peptide underlie the expression of acute post-traumatic headache, and drive the development of central sensitization, increasing vulnerability to headache triggers and promoting persistent post-traumatic headache. Early and continuous calcitonin-gene related peptide blockade following mild traumatic brain injury may represent a viable treatment option for post-traumatic headache and for the prevention of post-traumatic headache persistence. Abbreviations CA Cutaneous allodynia CGRP Calcitonin gene-related peptide mTBI Mild traumatic brain injury PTH Post-traumatic headache APTH Acute post-traumatic headache PPTH Persistent post-traumatic headache
A Next-Generation Single-Port Robotic Surgical System for Transoral Robotic Surgery
Magnuson, J. Scott , Weinstein, Gregory S., Chan, Jason Y. K. , Starmer, Heather M. , Tsang, Raymond K. , Wong, Eddy W. Y. , Rassekh, Christopher H. , Bedi, Nikita , Hong, Steven, O’Malley, Bert W. , Moore, Eric J. , Holsinger, F. Christopher , Wong, Eddy W. Y. , Orosco, Ryan K.

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | September 19, 2019 | Volume: 145 | Issue: 11 | Pages: 1027

10.1001/jamaoto.2019.2654 | PMID 31536129 Get It

Reconstruction of Complex Hemipelvectomy Defects: A 17-year Single-institutional Experience With Lower Extremity Free and Pedicled Fillet Flaps
Kreutz‐Rodrigues, Lucas , Weissler, Jason M., Carlsen, Brian T. , Rose, Peter S. , Bakri, Karim , Houdek, Matthew T.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | September 10, 2019 | Volume: 7 | Issue: 8S-1 | Pages: 108-108

10.1097/01.gox.0000584844.69674.a7 Get It

Intravenous Tranexamic Acid in Implant-based Breast Reconstruction Safely Reduces Hematoma Without Thromboembolic Events
Banuelos, Joseph, Weissler, Jason M., Harless, Christin A., Jacobson, Steven R., Tran, Nho V. , Nguyen, Minh-Doan T. , Manrique, Oscar J. , Martinez‐Jorge, Jorys

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | September 10, 2019 | Volume: 7 | Issue: 8S-1 | Pages: 87-87

10.1097/01.gox.0000584712.07862.aa Get It

MRI for Radiation Therapy Planning in Human Papillomavirus–associated Gynecologic Cancers
Venkatesan, Aradhana M. , Menias, Christine O. , Jones, Kyle M., Rauch, Gaiane M., Stafford, R Jason, Klopp, Ann H. , Rauch, Gaiane M. , Stafford, R. Jason , Venkatesan, Aradhana M

Mayo Clinic

RadioGraphics | September 9, 2019 | Volume: 39 | Issue: 5 | Pages: 1476-1500

10.1148/rg.2019180121 | PMID 31498740 Get It

Pan-TRK Immunohistochemistry
Harrison, Beth , Fowler, Elizabeth , Krings, Gregor , Chen, Yunn-Yi, Bean, Gregory R. , Fuhrmann, Laetitia , Barnick, Sandra E., Chen, Beiyun, Hosfield, Elizabeth M., Schnitt, Stuart J. , Fowler, Elizabeth, Chen, Yunn‐Yi , Vincent‐Salomon, Anne , Hornick, Jason L.

Mayo Clinic

American Journal of Surgical Pathology | September 9, 2019 | Volume: 43 | Issue: 12 | Pages: 1693-1700

10.1097/pas.0000000000001366 | PMID 31498178 Get It

Secretory carcinoma is a special-type breast carcinoma underpinned by a recurrent t(12;15)(p13;q25) translocation resulting in ETV6-NTRK3 gene fusion. Immunohistochemistry (IHC) using a pan-TRK antibody has been recently shown to help identify NTRK rearrangements in other tumor types. The purpose of this study was to assess the diagnostic utility of pan-TRK IHC in secretory carcinoma of the breast. Pan-TRK IHC was performed using a rabbit monoclonal antibody on whole sections of 24 breast secretory carcinomas and tissue microarray sections of other breast carcinoma types (n=203) and histologic mimics (n=15). Cases were assessed for staining intensity and localization. The 24 patients with secretory carcinoma had a median age of 44 years and a median tumor size of 1.0 cm. ETV6 fluorescence in situ hybridization was positive in all cases tested (n=20). Twenty-three cases (95.8%) showed staining with pan-TRK, which was exclusively nuclear in 19, primarily nuclear with weak cytoplasmic staining in 3, and primarily cytoplasmic with focal nuclear staining in 1. The nuclear staining was diffuse in 17 and at least focally strong in 17. The only pan-TRK negative case was a core biopsy with limited tumor. Among the 203 nonsecretory carcinomas, 21 (10.3%) showed focal, weak nuclear staining in <5% of tumor cells and 1 (0.5%) showed focal membranous staining. All histologic mimics were negative. In conclusion, diffuse and/or at least focally strong nuclear pan-TRK staining is a sensitive and specific marker for secretory carcinoma of the breast.
ESRA19-0430 Latex DYE confirmation of local anesthetic spread in pericapsular nerve group (PENG) block
Hall, Jason, Clendenen, Steven R.

Mayo Clinic

E-Poster Viewing Abstracts | August 30, 2019 | Volume: No volume available | Issue: No issue available | Pages: A213.2-A214

10.1136/rapm-2019-esraabs2019.371 Get It